about
Using Cost-Effectiveness Analysis to Address Health Equity Concerns.Distributional cost-effectiveness analysis in low-and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia.Cost-effectiveness analysis of a multi-dimensional intervention to reduce inappropriate antibiotic prescribing for children with upper respiratory tract infections in ChinaAlternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCTLevofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trialCost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South AfricaWhat factors affect patients' access to healthcare? Protocol for an overview of systematic reviewsProphylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
P50
Q37684773-CAC6DC07-4366-425B-8085-2CED8CC7E55FQ47564040-1B9E9130-A19A-493D-B8FD-68F0B03B11E3Q58899823-CF1C298C-D5C5-438F-80A1-5BF0201852A5Q58899834-639BE66F-8E50-4210-BF8F-F207CB015B6AQ91023570-A648675F-5CB0-445E-91C9-970F8B75B9BDQ92079350-12AA5761-B3CE-4FF8-AC13-4687CB3B5324Q92886300-E1FA5BE3-69EB-4251-9A11-4F180777DDA3Q95818969-4185E5BE-FDCE-4548-BFC3-D6B070A76834
P50
description
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Bryony Dawkins
@ast
Bryony Dawkins
@en
Bryony Dawkins
@en-gb
Bryony Dawkins
@es
Bryony Dawkins
@nl
Bryony Dawkins
@sl
type
label
Bryony Dawkins
@ast
Bryony Dawkins
@en
Bryony Dawkins
@en-gb
Bryony Dawkins
@es
Bryony Dawkins
@nl
Bryony Dawkins
@sl
prefLabel
Bryony Dawkins
@ast
Bryony Dawkins
@en
Bryony Dawkins
@en-gb
Bryony Dawkins
@es
Bryony Dawkins
@nl
Bryony Dawkins
@sl
P106
P31
P496
0000-0002-7038-1975